Naltrexone to keep a drug-free condition

Research Communications in Alcohol and Substances of Abuse

Volumn 20, Issue 3-4, 1999, Pages 91-98

  Stella, Luigi ^d   Cassese, Francesco ^b   Barone, Saverio ^b   Barchetta, Antonio ^b   Iacobelli, Massimo ^c   Motola, Giulia ^a   Mazzeo, Filomena ^a   Rossi, Francesco ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b ASL NA 4   (Italy)

^c Crinos Biological Research Laboratories   (Italy)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

DIAMORPHINE; KAPPA OPIATE RECEPTOR ANTAGONIST; METHADONE; MORPHINE; MU OPIATE RECEPTOR ANTAGONIST; NALOXONE; NALTREXONE; OPIATE; OPIATE ANTAGONIST; PRAZEPAM;

ANOREXIA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DETOXIFICATION; DRUG URINE LEVEL; EXCITABILITY; FAMILY LIFE; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HYPERALGESIA; INSOMNIA; MAJOR CLINICAL STUDY; MALE; METHADONE TREATMENT; OPIATE ADDICTION; PATIENT COMPLIANCE; PSYCHOTHERAPY; RELAPSE; REMISSION; WELLBEING;

EID: 0033513460     PISSN: 10808388     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Aley, K.O. and Levine J.D. (1997).: Different mechanisms mediate development and expression of tolerance and dependence for peripheral mu-opiod antinociception in rat. Neuroscience 17 (20): 80148-8023.
2. Carnish, J.W., Metzger, D., Woody, G.E., Wilson, D., McLellan, A.T., Vordergrift, B. and O'Brein C.P. (1997).: Naltrexone pharmacotherapy for opioid dependent federal probationes. J. Substan. Abuse Treat. 14: 529-534.
3. Charney, D.S., Redmond, D.E., Galloway, M.P., Kleber, H.D. and Heninger G.R.(1984).: Naltrexone precipitated opiate withdrawal in methadone-addicted human subjects: evidence for noradrenergic hyperactivity. Life Sci. 35: 1263-1267.
4. Di Chiara G. (1995).; The role of dopamine in drug abuse viewed from the perspective of its role in motivation. Drug and Alcohol Dependence 38: 95-137.
5. Foss, J.F., O'Connor, M.F., Yuan, C.S., Murphy, M., Moss, J. and Roizen, M.F.(1997).: Safety and tolerance of methylnaltrexone in healthy humans: a randomized, placebo-controlled, intravenous, ascending-dose, pharmacokinetic study. J. Clin. Pharmacol. 37: 25-30.
6. Gonzales, N.M, Campbell, M., Small, A.M., Shay, E., Bluhm, L.D., Adams, P.B. and Foltz, R.L. (1994).: Naltrexone plasma levels, clinicals response and effect on weight in children. Drugs 30: 203-208.
7. Gonzalez, J.P. and Brodgan, R.N. (1988).: Naltrexone: A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of opioid dependence. Drugs 35: 190-213.
8. Ibuki, T., Dunbar, S.A. and Yaksh, T.L. (1997).: Effect of transient naloxone antagonism on tolerance development in rats receiving continuous spinal morphine infusion. Pain 70 (2-3): 125-132.
9. Hathaway, S.R. and Mckinley, J.C. (1996).: Minnesota. Multiphasic Personality Inventory-2 (MMPI-2) Minnesota University Press, Organizzazioni Speciali eds Firenze.
10. Liferido, C. and Gallino G. (1993).: Il naltrexone nella relazione terapeutica in caso di abuso e dipendenza da oppiacei. Minerva Med. 84: 687-692.
11. Martin, W.S., Jasinski, D.R. and Mansky, P.A. (1984).: Naltrexone, an antagonist for the treatment of heroin dependence. Archives General Psychiatry. 28: 784-791.
12. McLellan A.T. Arndt, I.O. Metzger, D.S., Woody, G.E. and O' Brien, C.P. (1993).: The Effect of psychosocial services in substance abuse treatment. J. Amer. Med. Assocn. 269: 1953-1959.
13. Mello, N.K., Mendelson, J.H. and Bree, M.P. (1981).: Naltrexone effects on morphine and food self- administration in morphine-dependent Rhesus monkeys. J. Pharmacol. Exp. Ther. 214: 503-506.
14. Negus, S.S., Mello, N.K., Portoghese, P.S. and Lin, C.E. (1997).: Effects of kappa opioid on cocaine and morphine self-administration by rhesus monkeys. J. Pharmacol. Exp. Ther. 282: 44-55.
15. Roth, A., Hogan, I. and Forren, C. (1997).: Naltrexone plus group therapy for the treatment of opiate abusing health-care professionals. J. Subs. Abuse. Treat. 14: 19-22.
16. Shufman, E.N., Porat, S., Witztum, E., Gandacu, D. and Ginath, Y. (1994).: The efficacy of naltrexone in preventing re-abuse of heroin after detoxification. Biol. Psychiatry. 35: 935-945.
17. Simon, D.L. (1996).: The rationale for naltrexone therapy as an alternative to methadone treatment for opiate addiction. Conn. Med. 60: 683-685.
18. Stella, L., De Novellis V., Maione, S., Leyva, J., D'Amico, M., Berrino, L., Fillippelli, A. and Rossi F. (1995).: Relationship between purinergic and glutamatergic systems in the opiate withdrawal syndrome. Res. Comm. Mol. Path. Pharm. 87: 55-56.
19. 2a adenosine receptors in the opiate withdrawal syndrome. Res. Comm. Alcohol Substances Abuse. 18 (3-4): 141-148.
20. Sternieri, E., Ferrari, A., Bertolotti, M., Stefani, M. and Vitale, G. (1994).: Naltrexone: Aspetti di Farmacologia ed Applicazioni Cliniche. Boll. Farmadip. e Alcoolis., XVII: 17-21.
21. Zahn, P.K., Gysbers, D., Brennan, T.J. (1997).: Effect of systemic and intrathecal morphine in a rat model of postoperative pain. Anesthesiology 96 (5) 1066-1077.